MEDNAX Inc (NYSE:MD) has been given an average rating of “Hold” by the fourteen research firms that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $42.19.

Several analysts recently weighed in on MD shares. Zacks Investment Research cut shares of MEDNAX from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. Mizuho set a $36.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research note on Friday, February 8th. Credit Suisse Group reduced their price objective on shares of MEDNAX from $44.00 to $42.00 and set an “outperform” rating on the stock in a research note on Wednesday. Robert W. Baird reduced their price objective on shares of MEDNAX from $48.00 to $40.00 and set a “neutral” rating on the stock in a research note on Friday, November 2nd. Finally, BMO Capital Markets reduced their price objective on shares of MEDNAX from $48.00 to $43.00 and set a “market perform” rating on the stock in a research note on Friday, November 2nd.

Shares of NYSE:MD traded up $0.92 during trading on Tuesday, hitting $36.72. 1,049,158 shares of the company were exchanged, compared to its average volume of 1,168,677. The company has a market capitalization of $3.28 billion, a PE ratio of 10.46, a price-to-earnings-growth ratio of 1.23 and a beta of 0.69. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.43 and a current ratio of 1.40. MEDNAX has a 1-year low of $31.68 and a 1-year high of $63.04.

MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, February 7th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.09. The company had revenue of $932.70 million during the quarter, compared to the consensus estimate of $910.08 million. MEDNAX had a net margin of 7.37% and a return on equity of 10.35%. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.87 earnings per share. On average, equities analysts forecast that MEDNAX will post 3.42 EPS for the current fiscal year.

In other MEDNAX news, insider John C. Pepia sold 2,500 shares of the company’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $36.60, for a total transaction of $91,500.00. Following the sale, the insider now owns 28,583 shares of the company’s stock, valued at $1,046,137.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of MD. Bank of New York Mellon Corp increased its stake in shares of MEDNAX by 4.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,264,410 shares of the company’s stock worth $54,724,000 after purchasing an additional 54,120 shares during the last quarter. Bank of Montreal Can raised its position in MEDNAX by 112.3% in the 3rd quarter. Bank of Montreal Can now owns 446,487 shares of the company’s stock worth $20,834,000 after purchasing an additional 236,210 shares during the period. First Hawaiian Bank purchased a new position in MEDNAX in the 3rd quarter worth $557,000. GHP Investment Advisors Inc. raised its position in MEDNAX by 19.8% in the 3rd quarter. GHP Investment Advisors Inc. now owns 9,775 shares of the company’s stock worth $456,000 after purchasing an additional 1,615 shares during the period. Finally, Oakbrook Investments LLC raised its position in MEDNAX by 33.3% in the 3rd quarter. Oakbrook Investments LLC now owns 11,600 shares of the company’s stock worth $541,000 after purchasing an additional 2,900 shares during the period. 99.76% of the stock is currently owned by institutional investors and hedge funds.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

See Also: What are the reasons investors use put options?

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.